This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Exact Sciences Stock (NASDAQ:EXAS) Get Exact Sciences alerts:Sign Up Key Stats Today's Range$104.91▼$104.9150-Day Range$102.25▼$104.9152-Week Range$38.81▼$104.98VolumeN/AAverage Volume3.55 million shsMarket Capitalization$20.03 billionP/E RatioN/ADividend YieldN/APrice Target$98.21Consensus RatingReduce Company Overview Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults. Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development. In 2019, the company completed the acquisition of Genomic Health, bringing Oncotype DX® diagnostic tests into its offerings. These tests assess gene expression profiles in breast, prostate and other cancers to help guide treatment decisions, furthering Exact’s mission to advance precision oncology. Exact Sciences sells its products primarily in the United States and has extended its reach into selected international markets, including Europe and Australia. The company operates a network of laboratories and works closely with healthcare providers, payers and policy makers to support the adoption of its screening and diagnostic technologies. Exact Sciences also invests in clinical trials and real-world evidence studies to validate and refine its assays. Kevin Conroy, who joined Exact Sciences in 2015 and became president and chief executive officer in 2017, leads the company’s efforts to integrate molecular diagnostics into standard cancer care. Under his leadership, Exact has grown its commercial infrastructure and doubled down on research initiatives aimed at developing next-generation tests for multiple tumor types. The company remains focused on improving patient outcomes through earlier detection and more personalized treatment pathways.AI Generated. May Contain Errors. Read More Exact Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreEXAS MarketRank™: 0.15825658321 of 5 starsExact Sciences scored higher than 3% of companies evaluated by MarketBeat, and ranked 890th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingExact Sciences has received a consensus rating of Reduce. The company's average rating score is 1.95, and is based on no strong buy ratings, no buy ratings, 19 hold ratings, and 1 sell rating.Downside RiskExact Sciences has a consensus price target of $98.21, representing about 6.4% downside from its current price of $104.91.Amount of Analyst CoverageExact Sciences has received no research coverage in the past 90 days.Read more about Exact Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.58) to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -95.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -95.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioExact Sciences has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 8.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EXAS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.20% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXAS Stock News HeadlinesAbbott Labs shares fall as earnings beat offset by Exact Sciences acquisition dragApril 16, 2026 | proactiveinvestors.comExact Sciences CorporationMarch 26, 2026 | edition.cnn.comWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured to be lining up a Nasdaq debut before Thanksgiving… at a valuation of up to $2 trillion. But here’s what nobody’s talking about… A raise of about $100 billion doesn’t just make headlines. It puts an enormous spotlight on the AI industry. And as investors rush to find the next big opportunity in artificial intelligence, some of the most interesting plays may be hiding outside traditional AI stocks.October 27 at 1:00 AM | Crypto 101 Media (Ad)Abbott completes acquisition of Exact SciencesMarch 23, 2026 | finance.yahoo.comHow Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment StoryMarch 22, 2026 | finance.yahoo.com1 Mid-Cap Stock to Consider Right Now and 2 Facing HeadwindsMarch 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | businesswire.comSee More Headlines EXAS Stock Analysis - Frequently Asked Questions How were Exact Sciences' earnings last quarter? Exact Sciences Corporation (NASDAQ:EXAS) released its earnings results on Monday, November, 3rd. The medical research company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.11. The company's quarterly revenue was up 20.0% on a year-over-year basis. Read the conference call transcript. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and others. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), PayPal (PYPL), Micron Technology (MU) and Block (XYZ). Company Calendar Last Earnings11/03/2025Today10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EXAS's financial health is in the Green zone, according to TradeSmith. EXAS has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees7,200Year Founded1995Price Target and Rating Average Price Target for Exact Sciences$98.21 High Price Target$105.00 Low Price Target$75.00 Potential Upside/Downside-6.4%Consensus RatingReduce Rating Score (0-4)1.95 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth2.02Net Income-$207.95 million Net Margins-6.40% Pretax Margin-6.28% Return on Equity0.53% Return on Assets0.22% Debt Debt-to-Equity Ratio0.97 Current Ratio2.43 Quick Ratio2.17 Sales & Book Value Annual Sales$3.25 billion Price / Sales6.17 Cash Flow$1.27 per share Price / Cash Flow82.83 Book Value$12.58 per share Price / Book8.34Miscellaneous Outstanding Shares190,888,000Free Float188,597,000Market Cap$20.03 billion OptionableOptionable Beta1.41 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:EXAS) was last updated on 3/24/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
